A population-based study suggests a 7-year loss in those with MS.
To examine mortality associated with multiple sclerosis (MS), investigators in Canada used public health records linked to ICD-10 diagnostic coding, permitting both primary and contributing causes of death to be systematically evaluated. Each MS case in the dataset was matched to five control cases.
The study included 5797 individuals with MS and 28,807 matched controls. Mean age at MS diagnosis was 41 years, and mean duration of follow-up was 13 years. In the MS population, comorbidities included anxiety, depression, bipolar disorder, seizure disorder, fibromyalgia, and migraine, among others. Median survival was 76 years in the MS cohort and 83 years in the control cohort. The MS population had a 2.1-fold increased hazard of death. Death w…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)